[Carboplatin and paclitaxel induction chemotherapy for patients with oropharynx carcinoma].
BACKGROUND
Between June 1998 and January 2005 64 patients of the department of oto-rhino-laryngology, head and neck surgery in Kassel with primary resectable squamous cell carcinoma of the oropharynx underwent neoadjuvant induction therapy. Carboplatin and Paclitaxel were given 6 times once weekly. This combination has proofed to be successful in downstaging and extend survival in patients suffering from head and neck cancer. Afterwards tumor resection was performed in the initial extension of the carcinoma. Dependent on histological findings radiation therapy or radiochemotherapy was carried out.


METHODS
Retrospective data were collected to analyse the effect on the tumor site and cervical lymph node metatasis based on post-chemotherapy clinical and postoperative histological results. In addition correlation between clinical findings and histological outcome and a possible survival advantage in patients with under induction chemotherapy remitted carcinomas was performed.


RESULTS
The data showed no improvement in disease free survival in patients with complete remission of the primary tumor site but a significant prolonged survival time for patients with complete remission of the cervical lymph node metastasis.
Schneider
I
I
Asklepios Klinik Altona, Abteilung für HNO-Heilkunde (Chefarzt: Prof. Dr. T. Grundmann). ih.schneider@asklepios.com
Holzgraefe
M
M
Schröder
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate
D016190:Carboplatin; D017239:Paclitaxel